Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 6c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.69), $0.06 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KB Home (KBH) PT Lowered to $50 at RBC Capital
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)